Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19. We conducted a pragmatic open-label, parallel, cluster-randomised superiority trial in fo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	EClinicalMedicine 2021-12, Vol.42, p.101188-101188, Article 101188
Hauptverfasser:	Labhardt, Niklaus D, Smit, Mikaela, Petignat, Ianis, Perneger, Thomas, Marinosci, Annalisa, Ustero, Pilar, Diniz Ribeiro, Maria Pia, Ragozzino, Silvio, Nicoletti, Giovanni Jacopo, Faré, Pietro Benedetto, Andrey, Diego O, Jacquerioz, Frederique, Lebowitz, Dan, Agoritsas, Thomas, Meyer, Benjamin, Spechbach, Hervé, Salamun, Julien, Guessous, Idris, Chappuis, François, Kaiser, Laurent, Decosterd, Laurent Arthur, Grinsztejn, Beatriz, Bernasconi, Enos, Cardoso, Sandra Wagner, Calmy, Alexandra, Team, for the COPEP Study
Format:	Artikel
Sprache:	eng
Schlagworte:	Research paper
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Since the beginning of the COVID-19 pandemic, no direct antiviral treatment is effective as post-exposure prophylaxis (PEP). Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19. We conducted a pragmatic open-label, parallel, cluster-randomised superiority trial in four sites in Switzerland and Brazil between March 2020 to March 2021. Clusters were randomised to receive LPV/r PEP (400/100 mg) twice daily for 5 days or no PEP (surveillance). Exposure to SARS-CoV-2 was defined as a close contact of >15 minutes in
ISSN:	2589-5370 2589-5370
DOI:	10.1016/j.eclinm.2021.101188